Alison Chang, MD
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
14 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chang’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A139702 · Current
Licensed to practise in California · since 2015 · expires 2027-03-31 · Emory University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$4,688,333
Medicare paid this office $4,688,333 for 905 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 20 | $675,091 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $308,684 | None |
| Injection, vedolizumab, intravenous, 1 mg | 19 | $265,517 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $192,833 | None |
| Injection, tocilizumab, 1 mg | 14 | $99,898 | None |
See all 44 services
| Injection, pembrolizumab, 1 mg | 20 | $675,091 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $308,684 | None |
| Injection, vedolizumab, intravenous, 1 mg | 19 | $265,517 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 13 | $192,833 | None |
| Injection, tocilizumab, 1 mg | 14 | $99,898 | None |
| Injection, eptinezumab-jjmr, 1 mg | 15 | $78,633 | None |
| Return visit (30+ min) | 336 | $70,240 | $114 |
| Long return visit (40+ min) | 124 | $66,192 | $165 |
| Administration of chemotherapy into vein, 1 hour or less | 119 | $58,150 | $140 |
| Injection, golimumab, 1 mg, for intravenous use | 16 | $47,915 | None |
| Injection, denosumab, 1 mg | 15 | $43,857 | None |
| Injection, romosozumab-aqqg, 1 mg | 11 | $42,054 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 262 | $35,488 | $66 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 13 | $33,084 | $16 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $13,449 | None |
| New patient visit (45+ min) | 65 | $9,669 | $149 |
| Administration of additional new drug or substance into vein, 1 hour or less | 37 | $8,950 | $68 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 36 | $7,366 | $21 |
| Bcg live intravesical instillation, 1 mg | 21 | $5,931 | None |
| Injection, iron dextran, 50 mg | 20 | $5,272 | None |
| Injection of additional new drug or substance into vein | 77 | $5,171 | $16 |
| Administration of chemotherapy into vein, each additional hour | 51 | $5,060 | $29 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 225 | $4,916 | $15 |
| Instillation of anti-cancer drug into bladder | 21 | $4,715 | $89 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $4,587 | $78 |
| Injection of drug or substance into vein | 101 | $4,449 | $34 |
| Injection, zoledronic acid, 1 mg | 195 | $4,309 | None |
| Administration of additional new drug or substance into vein using push technique | 17 | $3,050 | $59 |
| Drawing of blood for a medical problem | 12 | $2,204 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 32 | $2,098 | $30 |
| Injection of drug or substance under skin or into muscle | 52 | $2,017 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 30 | $1,956 | $37 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 36 | $1,075 | $23 |
| Transfusion of blood or blood products | 11 | $936 | $47 |
| Injection, fosaprepitant, 1 mg | 23 | $678 | None |
| Infusion into a vein for hydration, each additional hour | 19 | $634 | $11 |
| Injection, carboplatin, 50 mg | 11 | $602 | None |
| Irrigation of implanted venous access drug delivery device | 14 | $505 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $468 | $20 |
| Infusion, normal saline solution, 250 cc | 214 | $144 | None |
| Injection, methylprednisolone sodium succinate, 5 mg | 14 | $133 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 43 | $133 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 42 | $128 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 34 | $60 | None |
Who their Medicare patients are
905 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 18% · Women 71% · Also on Medicaid 4% · Health risk score 1.31. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 60% · Cancer 42% · Coronary heart disease 22% · Chronic kidney disease 18% · Diabetes 17% · Atrial fibrillation 17% · Depression 14% · Heart failure 10% · COPD 8% · Stroke 5% · Dementia 4%.
The office billed $15,169,751, Medicare allowed $5,905,191 and paid $4,688,333; for 231,918 services of 142 kinds; $4,367,773 of it was for drugs given in the office and $320,560 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 905 | 231,918 | 77 | 1.31 | $15,169,751 | $4,688,333 |
| 2023 | 805 | 169,023 | 77 | 1.27 | $11,296,966 | $3,384,973 |
| 2022 | 749 | 193,930 | 77 | 1.34 | $10,324,211 | $3,156,015 |
| 2021 | 534 | 122,921 | 77 | 1.44 | $6,936,510 | $2,157,126 |
| 2020 | 175 | 20,276 | 76 | 1.36 | $1,721,388 | $604,496 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 44 services
| Injection, pembrolizumab, 1 mg | 16 | $550,151 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $275,591 | None |
| Injection, vedolizumab, intravenous, 1 mg | 16 | $192,787 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 12 | $162,693 | None |
| Injection, tocilizumab, 1 mg | 15 | $102,951 | None |
| Long return visit (40+ min) | 134 | $67,514 | $169 |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $64,145 | None |
| Administration of chemotherapy into vein, 1 hour or less | 110 | $51,986 | $145 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 11 | $48,550 | $23 |
| Return visit (30+ min) | 250 | $46,560 | $112 |
| Injection, denosumab, 1 mg | 14 | $44,972 | None |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $39,784 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 209 | $31,386 | $70 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 41 | $22,521 | None |
| New patient visit (45+ min) | 81 | $12,158 | $150 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 32 | $6,925 | $22 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 13 | $6,790 | $179 |
| Bcg live intravesical instillation, 1 mg | 20 | $6,154 | None |
| Administration of chemotherapy into vein, each additional hour | 51 | $5,736 | $30 |
| Administration of additional new drug or substance into vein, 1 hour or less | 31 | $5,586 | $71 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $5,539 | $80 |
| Instillation of anti-cancer drug into bladder | 21 | $4,850 | $88 |
| Injection of additional new drug or substance into vein | 61 | $4,837 | $17 |
| Administration of additional new drug or substance into vein using push technique | 18 | $4,714 | $60 |
| Injection, zoledronic acid, 1 mg | 149 | $4,592 | None |
| Administration of chemotherapy into vein using push technique | 11 | $3,238 | $112 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 46 | $2,668 | $37 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 31 | $2,610 | $31 |
| Injection of drug or substance into vein | 56 | $2,515 | $36 |
| Injection, leucovorin calcium, per 50 mg | 13 | $2,096 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 46 | $1,799 | $25 |
| Injection of drug or substance under skin or into muscle | 48 | $1,698 | $14 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $1,415 | $74 |
| Injection, fluorouracil, 500 mg | 16 | $1,103 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 16 | $940 | $21 |
| Injection, fosaprepitant, 1 mg | 14 | $563 | None |
| Infusion into a vein for hydration, each additional hour | 27 | $460 | $14 |
| Injection, oxaliplatin, 0.5 mg | 11 | $443 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 43 | $159 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 36 | $154 | None |
| Infusion, normal saline solution, 250 cc | 174 | $122 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 11 | $68 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 29 | $68 | None |
| Unclassified drugs | 13 | $10 | None |
2022: 47 services
| Injection, pembrolizumab, 1 mg | 17 | $396,246 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 14 | $175,697 | None |
| Injection, vedolizumab, intravenous, 1 mg | 14 | $165,891 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 15 | $87,244 | $38 |
| Injection, denosumab, 1 mg | 22 | $63,907 | None |
| Administration of chemotherapy into vein, 1 hour or less | 138 | $61,060 | $150 |
| Long return visit (40+ min) | 116 | $58,663 | $173 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 12 | $49,627 | $148 |
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $48,209 | None |
| Return visit (30+ min) | 209 | $39,363 | $113 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 56 | $37,334 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 157 | $27,313 | $73 |
| New patient visit (45+ min) | 86 | $13,188 | $153 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $12,801 | $83 |
| Administration of additional new drug or substance into vein, 1 hour or less | 43 | $9,840 | $73 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 18 | $8,907 | $178 |
| Administration of chemotherapy into vein, each additional hour | 75 | $7,742 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 52 | $7,032 | $32 |
| Injection of additional new drug or substance into vein | 92 | $6,197 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 25 | $5,139 | $22 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 63 | $5,006 | $36 |
| Bcg live intravesical instillation, 1 mg | 17 | $4,831 | None |
| New patient visit (60+ min) | 22 | $4,677 | $213 |
| Instillation of anti-cancer drug into bladder | 19 | $3,946 | $88 |
| Administration of additional new drug or substance into vein using push technique | 15 | $3,678 | $62 |
| Injection, zoledronic acid, 1 mg | 121 | $3,546 | None |
| Injection of drug or substance into vein | 72 | $3,062 | $40 |
| Injection of drug or substance under skin or into muscle | 64 | $2,588 | $14 |
| Injection, leucovorin calcium, per 50 mg | 15 | $2,346 | None |
| Telephone medical discussion with physician, 11-20 minutes | 24 | $2,012 | $75 |
| Drawing of blood for a medical problem | 11 | $1,698 | $106 |
| Injection, docetaxel, 1 mg | 13 | $1,651 | None |
| Injection, fosaprepitant, 1 mg | 28 | $1,447 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 33 | $1,264 | $24 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,207 | $101 |
| Injection, fluorouracil, 500 mg | 18 | $1,049 | None |
| Injection, carboplatin, 50 mg | 19 | $1,027 | None |
| Injection, paclitaxel, 1 mg | 16 | $994 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 14 | $959 | $21 |
| New patient visit (30+ min) | 12 | $729 | $61 |
| Injection, oxaliplatin, 0.5 mg | 14 | $592 | None |
| Irrigation of implanted venous access drug delivery device | 11 | $440 | $29 |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $183 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 25 | $180 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 52 | $145 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 43 | $115 | None |
| Unclassified drugs | 11 | $4 | None |
2021: 42 services
| Injection, pembrolizumab, 1 mg | 11 | $190,184 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 12 | $74,985 | $50 |
| Injection, infliximab, excludes biosimilar, 10 mg | 16 | $66,770 | None |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 12 | $51,185 | $194 |
| Administration of chemotherapy into vein, 1 hour or less | 117 | $49,414 | $159 |
| Injection, denosumab, 1 mg | 18 | $45,320 | None |
| Return visit (30+ min) | 153 | $41,721 | $124 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 108 | $19,439 | $79 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 34 | $18,776 | None |
| New patient visit (45+ min) | 110 | $16,830 | $153 |
| Administration of additional new drug or substance into vein, 1 hour or less | 39 | $8,444 | $77 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 66 | $7,260 | $33 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 15 | $6,532 | $167 |
| Administration of chemotherapy into vein, each additional hour | 54 | $5,915 | $33 |
| Injection of additional new drug or substance into vein | 82 | $5,640 | $18 |
| Long return visit (40+ min) | 23 | $4,364 | $175 |
| Telephone medical discussion with physician, 11-20 minutes | 37 | $3,629 | $68 |
| Administration of additional new drug or substance into vein using push technique | 19 | $3,434 | $66 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $3,265 | $23 |
| Short return visit (20+ min) | 27 | $3,210 | $84 |
| Bcg live intravesical instillation, 1 mg | 14 | $2,879 | None |
| New patient visit (30+ min) | 28 | $2,325 | $83 |
| Injection, zoledronic acid, 1 mg | 56 | $2,315 | None |
| Injection of drug or substance into vein | 31 | $2,261 | $44 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 39 | $2,216 | $35 |
| Injection of drug or substance under skin or into muscle | 60 | $2,056 | $14 |
| Injection, fosaprepitant, 1 mg | 21 | $1,885 | None |
| Instillation of anti-cancer drug into bladder | 14 | $1,659 | $79 |
| Injection, leucovorin calcium, per 50 mg | 12 | $1,345 | None |
| Injection, paclitaxel, 1 mg | 19 | $1,042 | None |
| Telephone medical discussion with physician, 5-10 minutes | 17 | $911 | $46 |
| Injection, docetaxel, 1 mg | 12 | $897 | None |
| Injection, oxaliplatin, 0.5 mg | 11 | $839 | None |
| Injection, carboplatin, 50 mg | 20 | $776 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 11 | $701 | $22 |
| Injection, fluorouracil, 500 mg | 15 | $585 | None |
| Collection of blood sample from implanted device | 13 | $572 | $26 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 20 | $570 | $21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 69 | $221 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 57 | $152 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 46 | $92 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 12 | $76 | None |
2020: 8 services
| Administration of chemotherapy into vein, 1 hour or less | 34 | $6,916 | $150 |
| Return visit (30+ min) | 45 | $6,811 | $105 |
| New patient visit (45+ min) | 38 | $6,052 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 35 | $3,570 | $76 |
| Administration of chemotherapy into vein, each additional hour | 14 | $904 | $31 |
| Injection of additional new drug or substance into vein | 23 | $650 | $17 |
| Injection of drug or substance under skin or into muscle | 20 | $354 | $14 |
| Injection, ondansetron hydrochloride, per 1 mg | 12 | $17 | None |
Drugs they prescribed that Part D paid
$4,493,516
Pharmacies billed $4,493,516 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,273 generic and fewer than 11 brand-name prescriptions · $4,493,516 in drug cost · 45 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenalidomide | 52 | $772,812 | $14,862 |
| Erleada | 48 | $579,459 | $12,072 |
| Ibrance | 26 | $441,779 | $16,992 |
| Revlimid | 20 | $404,643 | $20,232 |
| Zejula | 13 | $313,172 | $24,090 |
See all 31 drugs
| Lenalidomide | 52 | $772,812 | $14,862 |
| Erleada | 48 | $579,459 | $12,072 |
| Ibrance | 26 | $441,779 | $16,992 |
| Revlimid | 20 | $404,643 | $20,232 |
| Zejula | 13 | $313,172 | $24,090 |
| Tagrisso | 16 | $273,745 | $17,109 |
| Verzenio | 14 | $220,289 | $15,735 |
| Calquence | 12 | $185,771 | $15,481 |
| Nubeqa | 11 | $148,542 | $13,504 |
| Brukinsa | 11 | $105,775 | $9,616 |
| Eliquis | 64 | $90,186 | $1,409 |
| Abiraterone Acetate | 21 | $50,694 | $2,414 |
| Xarelto | 20 | $27,887 | $1,394 |
| Exemestane | 90 | $14,888 | $165 |
| Anastrozole | 289 | $6,918 | $24 |
| Letrozole | 191 | $4,959 | $26 |
| Hydroxyurea | 108 | $3,101 | $29 |
| Raloxifene | 25 | $1,826 | $73 |
| Dexamethasone | 45 | $1,348 | $30 |
| Tamoxifen Citrate | 33 | $693 | $21 |
| Acyclovir | 43 | $626 | $15 |
| Potassium Chloride | 34 | $473 | $14 |
| Prochlorperazine Maleate | 41 | $471 | $11 |
| Prednisone | 53 | $346 | $7 |
| Ondansetron | 38 | $289 | $8 |
| Gabapentin | 21 | $263 | $13 |
| Diphenoxylate-Atropine | 14 | $173 | $12 |
| Lorazepam | 34 | $106 | $3 |
| Furosemide | 15 | $39 | $3 |
| Sulfamethoxazole-Trimethoprim | 17 | $28 | $2 |
| Alendronate | 11 | $19 | $2 |
Year by year
| 2024 | 1,633 | 392 | None | None | $4,493,516 |
| 2023 | 1,183 | 293 | 1% (16) | None | $2,742,814 |
| 2022 | 738 | 189 | 3% (23) | None | $1,662,759 |
| 2021 | 312 | 90 | 5% (17) | None | $185,395 |
| 2020 | 59 | 31 | None | None | $47,587 |
| 2019 | 41 | 20 | None | None | $11,364 |
| 2018 | 60 | 29 | None | None | $2,319 |
| 2017 | 707 | 97 | 7% (51) | None | $100,072 |
| 2016 | 617 | 93 | 10% (63) | None | $58,833 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Revlimid | 24 | $553,828 | $23,076 |
| Ibrance | 31 | $528,332 | $17,043 |
| Erleada | 32 | $449,437 | $14,045 |
| Tagrisso | 13 | $223,535 | $17,195 |
| Verzenio | 13 | $205,214 | $15,786 |
| Abiraterone Acetate | 23 | $75,685 | $3,291 |
| Eliquis | 54 | $71,309 | $1,321 |
| Xarelto | 21 | $27,572 | $1,313 |
| Exemestane | 46 | $13,439 | $292 |
| Anastrozole | 234 | $7,911 | $34 |
| Letrozole | 140 | $4,665 | $33 |
| Hydroxyurea | 49 | $2,199 | $45 |
| Raloxifene | 17 | $2,177 | $128 |
| Tamoxifen Citrate | 23 | $825 | $36 |
| Acyclovir | 43 | $700 | $16 |
| Prochlorperazine Maleate | 45 | $549 | $12 |
| Dexamethasone | 23 | $463 | $20 |
| Ondansetron | 32 | $396 | $12 |
| Gabapentin | 15 | $317 | $21 |
| Famotidine | 14 | $265 | $19 |
| Lorazepam | 37 | $213 | $6 |
| Prednisone | 38 | $207 | $5 |
| Diphenoxylate-Atropine | 15 | $176 | $12 |
| Sulfamethoxazole-Trimethoprim | 19 | $96 | $5 |
2022: 16 drugs
| Revlimid | 28 | $533,160 | $19,041 |
| Erleada | 17 | $213,702 | $12,571 |
| Tagrisso | 12 | $181,609 | $15,134 |
| Eliquis | 41 | $50,373 | $1,229 |
| Xarelto | 29 | $30,161 | $1,040 |
| Abiraterone Acetate | 13 | $10,015 | $770 |
| Anastrozole | 145 | $3,471 | $24 |
| Dexamethasone | 51 | $1,327 | $26 |
| Hydroxyurea | 30 | $994 | $33 |
| Letrozole | 34 | $899 | $26 |
| Acyclovir | 32 | $707 | $22 |
| Ondansetron | 28 | $497 | $18 |
| Prochlorperazine Maleate | 42 | $454 | $11 |
| Prednisone | 31 | $223 | $7 |
| Lorazepam | 31 | $150 | $5 |
| Diphenoxylate-Atropine | 11 | $103 | $9 |
2021: 10 drugs
| Eliquis | 26 | $21,483 | $826 |
| Letrozole | 22 | $1,126 | $51 |
| Anastrozole | 22 | $530 | $24 |
| Acyclovir | 18 | $404 | $22 |
| Prochlorperazine Maleate | 23 | $334 | $15 |
| Dexamethasone | 12 | $325 | $27 |
| Ondansetron | 12 | $225 | $19 |
| Prednisone | 24 | $192 | $8 |
| Hydroxyurea | 11 | $176 | $16 |
| Lorazepam | 21 | $169 | $8 |
2020: 1 drug
| Prochlorperazine Maleate | 12 | $170 | $14 |
2017: 18 drugs
| Spiriva | 13 | $7,605 | $585 |
| Metoprolol | 24 | $996 | $41 |
| Hydrocodone-Acetaminophen | 43 | $946 | $22 |
| Gabapentin | 26 | $466 | $18 |
| Atorvastatin | 37 | $400 | $11 |
| Levetiracetam | 15 | $250 | $17 |
| Levothyroxine | 13 | $235 | $18 |
| Omeprazole | 25 | $224 | $9 |
| Potassium Chloride | 19 | $217 | $11 |
| Pantoprazole | 15 | $196 | $13 |
| Finasteride | 15 | $184 | $12 |
| Furosemide | 32 | $180 | $6 |
| Famotidine | 17 | $173 | $10 |
| Lisinopril | 27 | $137 | $5 |
| Amlodipine Besylate | 29 | $94 | $3 |
| Carvedilol | 14 | $80 | $6 |
| Metformin | 14 | $44 | $3 |
| Metoprolol | 13 | $34 | $3 |
2016: 12 drugs
| Novolog | 15 | $4,056 | $270 |
| Lantus | 11 | $2,790 | $254 |
| Hydrocodone-Acetaminophen | 52 | $1,424 | $27 |
| Atorvastatin | 23 | $461 | $20 |
| Omeprazole | 28 | $458 | $16 |
| Gabapentin | 31 | $212 | $7 |
| Levothyroxine | 13 | $160 | $12 |
| Metformin | 24 | $119 | $5 |
| Amlodipine Besylate | 17 | $113 | $7 |
| Lisinopril | 22 | $71 | $3 |
| Citalopram Hbr | 11 | $69 | $6 |
| Furosemide | 14 | $42 | $3 |
Money from drug and device companies
$218 in 2025
| 2025 | 3 | 4 | None | $218 |
| 2024 | 2 | 2 | None | $262 |
| 2023 | 1 | 1 | None | $25 |
| 2022 | 2 | 3 | None | $243 |
| 2021 | 1 | 2 | None | $213 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $166 | 2 payments
|
| Caris MPI | Mi Cancer Seek | $30 | 1 payment
|
| Gilead Sciences | Trodelvy | $22 | 1 payment
|
See all 4 published payments
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-19 | Enhertu | $43 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-06 | Enhertu | $123 |
| Caris MPI | Meals · 2025-05-05 | Mi Cancer Seek | $30 |
| Gilead Sciences | Meals · 2025-02-11 | Trodelvy | $22 |
See earlier years (2024, 2023, 2022, 2021)
2024: $262
| AstraZeneca Pharmaceuticals LP | Enhertu | $162 | 1 payment
|
| Aveo Pharmaceuticals | Fotivda | $100 | 1 payment
|
2023: $25
| Pfizer | Ibrance | $25 | 1 payment
|
2022: $243
| GlaxoSmithKline | Zejula | $211 | 2 payments
|
| Pfizer | Ibrance | $32 | 1 payment
|
2021: $213
| GlaxoSmithKline | Zejula | $213 | 2 payments
|
Professional record
- NPI
- 1205253465
- Licence
- CA A139702California A139702: Current · expires 2027-03-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-03-26
- NPI last updated
- 2020-08-03
- NPI record certified
- 2020-08-03
This is when the NPI record was last certified, not a medical board exam.